After-Hours Stock Movers: Immunic Inc (NASDAQ:IMUX) 76% LOWER; announced the outcome of a pre-planned interim group-level data analysis of its phase 1b clinical trial of IMU-935 in...
Immunic Inc. (NASDAQ:IMUX) reported Q2 EPS of ($0.72), $0.01 better than the analyst estimate of ($0.73).
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is focused on three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (RORyt), an immune cell-specific isoform of RORy; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis (MS), psoriasis and gastrointestinal diseases.
|Average||21.17 (+844.94% Upside)|
|No. of Analysts||6|